6,11-dihydro-5H-benzo[b]pyrido[3,2-f]azepine | 21100-37-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯氮卓类
• 英文名称: 6,11-dihydro-5H-benzo[b]pyrido[3,2-f]azepine
• 英文别名: 6,11-dihydro-5H-pyrido[2,3-b][1]benzazepine
• CAS: 21100-37-8
• 化学式: C₁₃H₁₂N₂
• 分子量: 196.252
• InChiKey: RBCAAHDEDUPUSR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  15
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.15
• 拓扑面积：
  24.9
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  6,11-dihydro-5H-benzo[b]pyrido[3,2-f]azepine 以 二氯甲烷 、 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 反应 15.0h， 生成 3-(5H-benzo[b]pyrido[3,2-f]azepin-11(6H)-yl)-3-oxopropanenitrile
  参考文献：
  名称：

  [EN] TRICYCLIC HETEROCYCLES AS ANTICANCER AGENTS
  [FR] HÉTÉROCYCLES TRICYCLIQUES EN TANT QU'AGENTS ANTICANCÉREUX

  摘要：

  揭示了对FOXO转录因子蛋白的三环化学调节剂。这些化合物可用于治疗癌症、年龄相关的蛋白质毒性、压力诱导的抑郁症、炎症和痤疮。这些化合物属于以下和类似的类别（i）、（ii）和（iii），其中Het是芳香杂环环，Y是各种侧链和环的连接点。这类化合物的一个例子是4-氯-N-(3-(10,11-二氢-5H-苯并[b]吡啶[2,3-f]氮杂环-5-基)丙基)苯磺酰胺（iv）。

  公开号：

  WO2014130534A1

文献信息

• [EN] COMPOUNDS AND THEIR USE AS BACE1 INHIBITORS<br/>[FR] COMPOSÉS ET LEUR UTILISATION EN TANT QU'INHIBITEURS DE BACE1
  申请人：ALLGENESIS BIOTHERAPEUTICS INC

  公开号：WO2016172255A1

  公开（公告）日：2016-10-27

  The present invention relates to compounds of Formula (I) or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein X, Y, Z, Q, W, m, u, ring (A), R2, R3, R4, R5 and R6, are as defined in the specification and claims. The present invention provides a pharmaceutical composition containing the compounds of Formula (I) and a therapeutic method of treating and/or preventing Downs syndrome, β-amyloid angiopathy, disorders associated with cognitive impairment, Alzheimer's disease, memory loss, attention deficit symptoms associated with Alzheimer's disease, neurodegenerative diseases, pre-senile dementia, senile dementia and dementia associated with Parkinson's disease, Alzheimer's disease and/or Down syndrome, age-related macular degeneration (AMD), glaucoma, olfactory function impairment, traumatic brain injury, progressive muscle diseases, Type II diabetes mellitus and cardiovascular diseases (stroke).

  本发明涉及式（I）的化合物或其立体异构体、互变异构体、或其药学上可接受的盐或溶剂，其中X、Y、Z、Q、W、m、u、环（A）、R2、R3、R4、R5和R6如规范和权利要求中所定义。本发明提供了含有式（I）化合物的药物组合物，以及治疗和/或预防唐氏综合征、β-淀粉样血管病、与认知损伤相关的疾病、阿尔茨海默病、记忆丧失、与阿尔茨海默病相关的注意力缺陷症状、神经退行性疾病、早老性痴呆、老年性痴呆和与帕金森病、阿尔茨海默病和/或唐氏综合征相关的痴呆、年龄相关性黄斑变性（AMD）、青光眼、嗅觉功能障碍、创伤性脑损伤、进行性肌肉疾病、2型糖尿病和心血管疾病（中风）的治疗方法。
• TRICYCLIC HETEROCYCLES AS ANTICANCER AGENTS
  申请人：ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI

  公开号：US20150376191A1

  公开（公告）日：2015-12-31

  Tricyclic chemical modulators of FOXO transcription factor proteins are disclosed. The compounds are useful to treat cancer, age-onset proteotoxicity, stress-induced depression, inflammation, and acne. The compounds are of the following and similar genera: in which Het is an aromatic heterocyclic ring and Y is a point of attachment of various side chains and rings. An example of such a compound is 4-chloro-N-(3-(10,11-dihydro-5H-benzo[b]pyrido[2,3-f]azepin-5-yl)propyl)benzenesulfonamide:

  本发明公开了三环化学调节剂FOXO转录因子蛋白的化合物。这些化合物可用于治疗癌症、年龄相关的蛋白毒性、压力诱导性抑郁症、炎症和痤疮。这些化合物属于以下及类似属：其中Het是芳香族杂环环，Y是各种侧链和环的连接点。这样一个化合物的例子是4-氯-N-（3-（10,11-二氢-5H-苯并[b]吡啶[2,3-f]氮杂环-5-基）丙基）苯磺酰胺。
• Compounds and their use as BACE1 inhibitors
  申请人：ALLGENESIS BIOTHERAPEUTICS, INC.

  公开号：US10870635B2

  公开（公告）日：2020-12-22

  The present invention relates to compounds of Formula (I) or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein X, Y, Z, Q, W, m, u, ring (A), R2, R3, R4, R5 and R6, are as defined in the specification and claims. The present invention provides a pharmaceutical composition containing the compounds of Formula (I) and a therapeutic method of treating and/or preventing Downs syndrome, 3-amyloid angiopathy, disorders associated with cognitive impairment, Alzheimer's disease, memory loss, attention deficit symptoms associated with Alzheimer's disease, neurodegenerative diseases, pre-senile dementia, senile dementia and dementia associated with Parkinson's disease, Alzheimer's disease and/or Down syndrome, age-related macular degeneration (AMD), glaucoma, olfactory function impairment, traumatic brain injury, progressive muscle diseases, Type II diabetes mellitus and cardiovascular diseases (stroke).

  本发明涉及式(I)化合物或其立体异构体、同分异构体或药学上可接受的盐或溶液，其中X、Y、Z、Q、W、m、u、环(A)、R2、R3、R4、R5和R6如说明书和权利要求书中所定义。本发明提供了一种含有式（I）化合物的药物组合物和一种治疗方法，用于治疗和/或预防唐氏综合征、3-淀粉样血管病、与认知障碍相关的疾病、阿尔茨海默病、记忆力减退、与阿尔茨海默病相关的注意力缺陷症状、神经退行性疾病、老年前期痴呆、老年期痴呆以及与帕金森病、阿尔茨海默病和/或唐氏综合征相关的痴呆、老年黄斑变性（AMD）、青光眼、嗅觉功能损伤、脑外伤、进行性肌肉疾病、II 型糖尿病和心血管疾病（中风）。
• Reengineered tricyclic anti-cancer agents
  作者：David B. Kastrinsky、Jaya Sangodkar、Nilesh Zaware、Sudeh Izadmehr、Neil S. Dhawan、Goutham Narla、Michael Ohlmeyer

  DOI：10.1016/j.bmc.2015.07.007

  日期：2015.10

  The phenothiazine and dibenzazepine tricyclics are potent neurotropic drugs with a documented but underutilized anti-cancer side effect. Reengineering these agents (TFP, CPZ, CIP) by replacing the basic amine with a neutral polar functional group (e.g., RTC-1, RTC-2) abrogated their CNS effects as demonstrated by in vitro pharmacological assays and in vivo behavioral models. Further optimization generated several phenothiazines and dibenzazepines with improved anti-cancer potency, exemplified by RTC-5. This new lead demonstrated efficacy against a xenograft model of an EGFR driven cancer without the neurotropic effects exhibited by the parent molecules. Its effects were attributed to concomitant negative regulation of PI3K-AKT and RAS-ERK signaling. (C) 2015 Elsevier Ltd. All rights reserved.
• COMPOUNDS AND THEIR USE AS BACE1 INHIBITORS
  申请人：Allgenesis Biotherapeutics Inc.

  公开号：EP3250035A1

  公开（公告）日：2017-12-06